Observational study of targeted agents in CLL
This AVEN-CLL study generates real-world evidence on fixed-duration venetoclax regimens across four AVEN hematology units. It collects clinical, biological, and treatment data, including NGS-based MRD, to assess effectiveness and safety. Outcomes, dose modifications, and adverse events are systematically recorded to confirm feasibility in routine care.
Microenvironment and leukemic resistance
This research develops in vitro models to probe venetoclax resistance via emerging mutations and pathway rewiring. Microenvironmental signals, notably Notch2 and the IDO1/AhR axis, are studied for their roles in survival and drug resistance. Using 2D and 3D cultures, the work targets quiescent, drug-tolerant CLL subsets to identify actionable vulnerabilities.
Trisomy 12 and del(13q) impact in CLL
This research examines coexisting trisomy 12 and del(13q)/miR‑15a/16‑1 loss and their effects on biology, prognosis, and venetoclax sensitivity. Integrated cytogenetics, flow cytometry, NGS, RT‑PCR, and RNA‑seq define disease profiles, while single-cell analyses map clonal architecture. CRISPR-based assays test functional consequences to refine risk stratification and inform personalized therapies.